New anticoagulants for the treatment of venous thromboembolism

Detalhes bibliográficos
Autor(a) principal: Fernandes,Caio Julio Cesar dos Santos
Data de Publicação: 2016
Outros Autores: Alves Júnior,José Leonidas, Gavilanes,Francisca, Prada,Luis Felipe, Morinaga,Luciana Kato, Souza,Rogerio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Pneumologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146
Resumo: Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.
id SBPT-1_3496db8ee6a4c8c7278f28345ba531d7
oai_identifier_str oai:scielo:S1806-37132016000200146
network_acronym_str SBPT-1
network_name_str Jornal Brasileiro de Pneumologia (Online)
repository_id_str
spelling New anticoagulants for the treatment of venous thromboembolismBlood coagulationVenous thromboembolism\therapyVenous thromboembolism\prevention and controlWorldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.Sociedade Brasileira de Pneumologia e Tisiologia2016-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146Jornal Brasileiro de Pneumologia v.42 n.2 2016reponame:Jornal Brasileiro de Pneumologia (Online)instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)instacron:SBPT10.1590/S1806-37562016042020068info:eu-repo/semantics/openAccessFernandes,Caio Julio Cesar dos SantosAlves Júnior,José LeonidasGavilanes,FranciscaPrada,Luis FelipeMorinaga,Luciana KatoSouza,Rogerioeng2016-05-05T00:00:00Zoai:scielo:S1806-37132016000200146Revistahttp://www.jornaldepneumologia.com.br/default.aspONGhttps://old.scielo.br/oai/scielo-oai.php||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br1806-37561806-3713opendoar:2016-05-05T00:00Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)false
dc.title.none.fl_str_mv New anticoagulants for the treatment of venous thromboembolism
title New anticoagulants for the treatment of venous thromboembolism
spellingShingle New anticoagulants for the treatment of venous thromboembolism
Fernandes,Caio Julio Cesar dos Santos
Blood coagulation
Venous thromboembolism\therapy
Venous thromboembolism\prevention and control
title_short New anticoagulants for the treatment of venous thromboembolism
title_full New anticoagulants for the treatment of venous thromboembolism
title_fullStr New anticoagulants for the treatment of venous thromboembolism
title_full_unstemmed New anticoagulants for the treatment of venous thromboembolism
title_sort New anticoagulants for the treatment of venous thromboembolism
author Fernandes,Caio Julio Cesar dos Santos
author_facet Fernandes,Caio Julio Cesar dos Santos
Alves Júnior,José Leonidas
Gavilanes,Francisca
Prada,Luis Felipe
Morinaga,Luciana Kato
Souza,Rogerio
author_role author
author2 Alves Júnior,José Leonidas
Gavilanes,Francisca
Prada,Luis Felipe
Morinaga,Luciana Kato
Souza,Rogerio
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Fernandes,Caio Julio Cesar dos Santos
Alves Júnior,José Leonidas
Gavilanes,Francisca
Prada,Luis Felipe
Morinaga,Luciana Kato
Souza,Rogerio
dc.subject.por.fl_str_mv Blood coagulation
Venous thromboembolism\therapy
Venous thromboembolism\prevention and control
topic Blood coagulation
Venous thromboembolism\therapy
Venous thromboembolism\prevention and control
description Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.
publishDate 2016
dc.date.none.fl_str_mv 2016-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000200146
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1806-37562016042020068
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Pneumologia e Tisiologia
publisher.none.fl_str_mv Sociedade Brasileira de Pneumologia e Tisiologia
dc.source.none.fl_str_mv Jornal Brasileiro de Pneumologia v.42 n.2 2016
reponame:Jornal Brasileiro de Pneumologia (Online)
instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron:SBPT
instname_str Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron_str SBPT
institution SBPT
reponame_str Jornal Brasileiro de Pneumologia (Online)
collection Jornal Brasileiro de Pneumologia (Online)
repository.name.fl_str_mv Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
repository.mail.fl_str_mv ||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br
_version_ 1750318346414325760